✨
AI Summary
- Sernova Corp. CEO Philip Toleikis details a stem cell-derived treatment for Type 1 Diabetes.
- The ongoing clinical trial aims for a functional cure, moving beyond symptom management.
- Toleikis shares his perspective on the future of regenerative medicine.
Guests on This Episode
PT
Philip Toleikis
1 podcast appearance